BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26530358)

  • 1. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    Adv Exp Med Biol; 2015; 867():27-39. PubMed ID: 26530358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Biomarkers in Screening for Cancer.
    Duffy MJ
    EJIFCC; 2010 Mar; 21(1):1-12. PubMed ID: 27683350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer screening-ultrasound; impact on ovarian cancer mortality.
    Kamal R; Hamed S; Mansour S; Mounir Y; Abdel Sallam S
    Br J Radiol; 2018 Oct; 91(1090):20170571. PubMed ID: 30102555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in clinical practice: a review focusing on common solid cancers.
    Duffy MJ
    Med Princ Pract; 2013; 22(1):4-11. PubMed ID: 22584792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper.
    Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP
    Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples.
    Guittet L; Bouvier V; Mariotte N; Vallee JP; Levillain R; Tichet J; Launoy G
    Int J Cancer; 2009 Sep; 125(5):1127-33. PubMed ID: 19431212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA in screening for prostate cancer: more good than harm or more harm than good?
    Duffy MJ
    Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
    Birnbaum JK; Feng Z; Gulati R; Fan J; Lotan Y; Wei JT; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2015 Apr; 24(4):677-82. PubMed ID: 25613117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of colorectal cancer with faecal occult blood test screening.
    Paimela H; Malila N; Palva T; Hakulinen T; Vertio H; Järvinen H
    Br J Surg; 2010 Oct; 97(10):1567-71. PubMed ID: 20603855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for colorectal cancer in Italy, 2009 survey.
    Zorzi M; Baracco S; Fedato C; Grazzini G; Sassoli De' Bianchi P; Senore C; Visioli CB; Cogo C
    Epidemiol Prev; 2011; 35(5-6 Suppl 5):55-77. PubMed ID: 22166350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy?
    van Dam L; Korfage IJ; Kuipers EJ; Hol L; van Roon AH; Reijerink JC; van Ballegooijen M; van Leerdam ME
    Eur J Cancer; 2013 Jul; 49(10):2321-30. PubMed ID: 23571149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
    Musil D; Tillich J
    Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up.
    Scholefield JH; Moss SM; Mangham CM; Whynes DK; Hardcastle JD
    Gut; 2012 Jul; 61(7):1036-40. PubMed ID: 22052062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer.
    Bechtold ML; Ashraf I; Nguyen DL
    South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.